[A trial of the use of low-molecular-weight heparin (fraksiparin) in myocardial infarct].
Efficacy and safety were studied of nonfractionated versus low-molecular heparines (NFH, LMH) in acute myocardial infarction (AMI). A total of 99 AMI patients entered the trial including those after thrombolytic therapy. The highest preventive effect in respect to both venous and arterial thrombosis was achieved at subcutaneous administration of NFH in twice daily dose 12500 U and LMH in a single daily dose 25000 U. High doses of LFH promoted hemorrhagic complications which were absent in administration of LMH. NFH had a proaggregant action on the platelets. It is concluded that LMH is an effective and safe modality in the treatment of AMI patients acting through inhibition of activity of blood coagulation factor X, antiaggregant effect on platelets, improving microrheology of red cells and activation of fibrinolysis.
Savenkov
M P
MP
Borshchevskaia
M V
MV
Gvozdkov
A L
AL
Semenova
E N
EN
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D006487:Hemostasis / Q000187:drug effects; D006493:Heparin / Q000008:administration & dosage / Q000009:adverse effects; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D013927:Thrombosis / Q000097:blood / Q000209:etiology / Q000517:prevention & control; D013997:Time Factors
D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D006493:Heparin